The short version of Research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
== Cell Turgor == Pressurized flow of latex has been studied in multiple Asclepias species as a form of defense in addition to the secondary metabolites stored in the latex. In order to augment the defense of the plant some non-articulated laticifer cells contain highly pressurized stores of latex. It has been noted that pressure may be produced by the osmotic uptake of water into the laticifer cell resulting in a turgid cell. When pierced the cell bursts and latex travels quickly through the canal system to stop the herbivore. A desert species, Bursera schlechtendalii, pressurizes the canals right where leaves attach to the stem so that when a grazer eats a leaf latex shoots out. This process is termed the “squirt gun” defense.
=== NIA T32 Training Program for Research Scientists in the Biology of Aging === The NIA T32 Training Program for Research Scientists in the Biology of Aging is one of the nation's premier institutional training programs dedicated to preparing the next generation of leaders in geroscience. Established through support from the National Institute on Aging (NIA), the program provides rigorous multidisciplinary research training for both predoctoral (PhD and MD/PhD) students and postdoctoral fellows pursuing careers in the basic, translational, and clinical biology of aging. For more than three decades, the program has trained investigators who have gone on to become independent scientists, faculty members, and leaders in academia, government, and industry, significantly contributing to advances in aging biology and age-related disease research. The overarching goal of the training program is to develop independent investigators capable of translating discoveries in the fundamental biology of aging into interventions that improve healthspan and reduce the burden of age-associated diseases. Trainees receive individualized, mentor-guided research experiences that integrate molecular, cellular, organismal, and translational approaches to understanding the mechanisms that drive biological aging. The curriculum emphasizes the principles of geroscience—the concept that targeting the biological processes of aging can simultaneously delay or prevent multiple chronic diseases—providing trainees with a broad scientific foundation while encouraging innovative, interdisciplinary research.
CI has a larger mass range than that of EI and can analyze molecules that EI may not be able to . CI also has the advantage of being less damaging to the sample molecule, so that less fragmentation occurs and more information about the original analyte can be determined. Photoionization (PI) was a method that was first applied as an ionization method to detecting gases separated by GC. Years later, it was also applied as a detector for LC, though the samples must be vaporized first to be detected by the photoionization detector. Eventually PI was applied to mass spectrometry, particularly as an ionization method for gas chromatography-mass spectrometry. Sample preparation for PI includes first ensuring the sample is in the gas phase. PI ionizes molecules by exciting the sample molecules with photons of light. This method only works if the sample and other components in the gas phase are excited by different wavelengths of light. It is important when preparing the sample, or photon source, that the wavelengths of ionization are adjusted to excite the sample analyte and nothing else.
== Determination of Beta Turns == Beta turns are another type of “short” or local secondary structure that is distinct from the more common helices, beta sheets or random coils. Beta turns are reasonably abundant (15%) and very important secondary structures in proteins. In particular, beta turns play a critical role in defining the topology of proteins. They also likely play a role in initiating early packing events during the protein folding process. In VADAR beta turns are identified under the BTURN header using standard Roman numeral notation (I = type I, II = type II, etc.). In VADAR, beta turns are identified using a combination of different pieces of information including hydrogen bond data, the location of previously identified secondary structures and the value of their local dihedral angles. In VADAR the classification and nomenclature used for beta turns follows the definitions proposed by Wilmot and Thornton.
The British government went against the advice of its generals and declined to send substantial reinforcements to South Africa before war broke out. Secretary of State for War Lansdowne did not believe the Boers were preparing for war and that if Britain were to send large numbers of troops, it would strike too aggressive a posture and possibly derail a negotiated settlement—or even encourage a Boer attack.
Sources: en.wikipedia.org
=== Filamentous fungi === Fungi are natural decomposers of many ecosystems. As a result, it is able to secrete large amounts of enzymes, more so than bacterial based systems. However, utilizing fungi as expression systems has seen several barriers, especially due to the lack of knowledge regarding fungal genetics due to its inherent complexity. The filamentous fungi specifically have been a host system of interest, and includes Penicillium (where penicillin was derived), Trichoderma reesei, and Aspergillus niger. Filamentous fungi are efficient at producing extracellular proteins, bypassing the additional step of cell breaking to extract proteins. Some also have inexpensive growth and media conditions. Fungi also contain glycolysation and modification capabilities that are helpful for eukaryotic proteins. Additionally, they have also successfully produced vaccine related proteins, and some filamentous fungi have been deemed GRAS by the FDA. However, the major drawback of using this host system is that yields are extremely low and not economically viable. Moreover, the low amount of protein that is produced is often degraded by fungal proteases. Some approaches to address this have been using protease deficient strains. Researchers are also attempting different gene disruption methods. With a better understanding of fungal gene regulation and expression, we can expect filamentous fungi to become a possibly viable host system.
===== North America ===== Canada - DMT is classified as a Schedule III drug under the Controlled Drugs and Substances Act, but is legal for religious groups to use. In 2017 the Santo Daime Church Céu do Montréal received religious exemption to use ayahuasca as a sacrament in their rituals. United States - DMT is classified in the United States as a Schedule I drug under the Controlled Substances Act of 1970. In 2019, it was decriminalized, along with other naturally derived psychedelics, in the city of Oakland after a campaign by Decriminalize Nature.
=== 2004 === 24 June Human Face Transplant, an Equinox Special, about Jacqui Saburido, after a drunk driver hit her car, work takes place at the University of Louisville School of Medicine; featured the work of John Barker in Kentucky, and his colleague Joe Banis; the French plastic surgeon Laurent Lantieri. Narrated by Lucy Briers, directed by Iain Scollay
== History == Faroese physician Niels Finsen is believed to be the father of modern light therapy. He used red light to treat smallpox lesions. He received the Nobel Prize in Physiology or Medicine in 1903. Scientific evidence for some of his treatments is lacking, and later eradication of smallpox and development of antibiotics for tuberculosis rendered light therapy obsolete for these diseases. Hungarian physician and surgeon Endre Mester (1903–1984) is credited with the discovery of the biological effects of low power lasers, which occurred a few years after the 1960 invention of the ruby laser and the 1961 invention of the helium–neon (HeNe) laser. Mester accidentally discovered that low-level ruby laser light could regrow hair during an attempt to replicate an experiment that showed that such lasers could reduce tumors in mice. The laser he was using was faulty and was not as powerful as believed. It failed to affect the tumors, but in places where the mice had been shaved in order to do the experiments, the hair grew back more quickly on the treated mice than on those among the control group. He published those results in 1967. Mester went on to show that low level HeNe light could accelerate wound healing in mice. By the 1970s, he was applying low level laser light to treat people with skin ulcers. In 1974, he founded the Laser Research Center at the Semmelweis Medical University in Budapest, and continued working there for the remainder of his life. His sons carried on his work and brought it to the United States.
Sources: en.wikipedia.org
Terminally ill patients in Oregon who have requested physician-assisted suicide have received lethal doses of barbiturates. The protocol has been highly effective in producing a so-called painless death, but the time required to cause death can be prolonged. Some patients have taken days to die, and a few patients have actually survived the process and have regained consciousness up to three days after taking the lethal dose. In a California legal proceeding addressing the issue of the lethal-injection cocktail being "cruel and unusual," state authorities said that the time to death following a single injection of a barbiturate could be as much as 45 minutes. Barbiturate overdoses typically cause death by depression of the respiratory center, but the effect is variable. Some patients may have complete cessation of respiratory drive, whereas others may only have depression of respiratory function. In addition, cardiac activity can last for a long time after cessation of respiration. Since death is pronounced after asystole, and given that the expectation is for a rapid death in lethal injection, multiple drugs are required, specifically potassium chloride to stop the heart. In fact, in the case of Clarence Ray Allen, a second dose of potassium chloride was needed to achieve this.
=== NNPC, NEITI Set Up Joint Committee to Strengthen Transparency === In keeping with the Transparency, Accountability, and Performance Excellence (TAPE) agenda of the Mele Kyari-led management of the Nigerian National Petroleum Corporation (NNPC), the corporation and the Nigeria Extractive Industries Transparency Initiative (NEITI) have set up a joint committee to deepen collaboration in order to promote transparency in the Oil and Gas Industry. Speaking at the inauguration of the NNPC-NEITI Joint Committee on Mainstreaming and Remedial Issues, group managing director of NNPC, Kyari, said the joint committee was part of efforts to further deepen the robust history of collaboration that both organisations had enjoyed over the years. He said NNPC was in complete sync with the activities of NEITI because it was the right of the over 200 million Nigerians who are the shareholders of the corporation to know everything about the operations of their company.
Valve announced Episode Three in May 2006, planning to release it by Christmas 2007. Concept art appeared in 2007. Valve released little information in the following years, with no clarity on whether further Half-Life games were coming. In 2011, Wired described Episode Three as vaporware. In 2017, Business Insider described it as "the world's most anticipated game", but said that it had become a "farce". Valve eventually canceled Episode Three and abandoned episodic development, as they wanted to create more ambitious games. According to the level designer Dario Casali, "We found ourselves creeping ever forward towards, 'Well, let's just keep putting more and more, and more, and more stuff in this game because we want to make it as good as we can,' and then we realized these episodes are turning more into sequels." The team became fatigued with Half-Life and struggled to discover new gameplay mechanics. The designer Robin Walker said Valve used Half-Life games to "solve some interesting collision of technology and art that had reared itself". Working on Episode Three, they failed to find a unifying idea that provided a sense of "wonderment, or opening, or expansion". Additionally, Valve had started developing a new game engine, Source 2. As developing Half-Life 2 and the original Source engine simultaneously had created problems, Valve delayed development of a new Half-Life until Source 2 was complete. After completing other projects, such as the multiplayer game Left 4 Dead (2008), the team felt the opportunity to create Episode Three had passed.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.